Salud financiera de hoja de balance de Eyenovia

Salud financiera controles de criterios 3/6

Eyenovia tiene un patrimonio de los accionistas total de $3.7M y una deuda total de $11.6M, lo que sitúa su ratio deuda-patrimonio en 311.1%. Sus activos y pasivos totales son $22.8M y $19.1M respectivamente.

Información clave

311.1%

Ratio deuda-patrimonio

US$11.57m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$7.19m
Patrimonio	US$3.72m
Total pasivo	US$19.08m
Activos totales	US$22.80m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Jan 30

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Oct 14

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Jun 27

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Oct 25

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Oct 05

Eyenovia names Michael Rowe as new CEO

Jul 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($11.7M) de EYEN no cubren sus pasivos a corto plazo ($15.8M).

Pasivo a largo plazo: Los activos a corto plazo de EYEN ($11.7M) superan a sus pasivos a largo plazo ($3.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de EYEN (117.8%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de EYEN ha crecido de 0% a 311.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: EYEN tiene suficiente cash runway para 3 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que EYEN disponga de suficiente cash runway para 3 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Eyenovia

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Recent updates

New minor risk - Profitability

New major risk - Market cap size

Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study

Eyenovia, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes

Eyenovia names Michael Rowe as new CEO